Gene Silencing, Immune Response, Regulation and Trials

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Silencing

Immune Response

Regulation

Trials

Cash round sets up trial of InteRNA’s microRNA for cancer

pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.

Trials

Trials Gene Silencing RNA Gene Expression

World RNA Day: What impact RNA it had on drug discovery?

Drug Discovery World

AUGUST 1, 2023

This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response. This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.

RNA

RNA Drugs Gene Silencing Vaccination

Clinical Research Informer

Cash round sets up trial of InteRNA’s microRNA for cancer

World RNA Day: What impact RNA it had on drug discovery?

Stay Connected